Avenue Therapeutics, Inc. financial data

Symbol
ATXI on OTC
Industry
Pharmaceutical Preparations
Location
1111 Kane Concourse, Suite 301, Bay Harbor Islands, FL
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Mar 31, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Debt-to-equity 33.5 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 3.15M shares -92.9%
Common Stock, Shares, Outstanding 2.11M shares +518%
Entity Public Float 3.91M USD -54.1%
Common Stock, Value, Issued 0 USD -100%
Weighted Average Number of Shares Outstanding, Basic 1.3M shares +817%
Weighted Average Number of Shares Outstanding, Diluted 8.2M shares +459%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 6.65M USD +8.38%
General and Administrative Expense 4.64M USD +11%
Operating Income (Loss) -11.3M USD +22.4%
Nonoperating Income (Expense) 69K USD -97.3%
Net Income (Loss) Attributable to Parent -3.08M USD -685%
Earnings Per Share, Basic -15.8 USD/shares +78.5%
Earnings Per Share, Diluted 0.06 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 2.59M USD +45.5%
Assets 2.67M USD +44.4%
Accounts Payable, Current 155K USD +98.7%
Liabilities, Current 816K USD -31.8%
Liabilities 816K USD -31.8%
Retained Earnings (Accumulated Deficit) -103M USD -12.8%
Stockholders' Equity Attributable to Parent 2.8M USD +76.8%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 1.86M USD +184%
Liabilities and Equity 2.67M USD +44.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.12M USD -98.3%
Net Cash Provided by (Used in) Financing Activities 4.53M USD +46.1%
Common Stock, Shares Authorized 200M shares +167%
Common Stock, Shares, Issued 2.11M shares +518%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Deferred Tax Assets, Valuation Allowance 35M USD -1.94%
Deferred Tax Assets, Gross 35M USD -1.94%
Deferred Tax Assets, Operating Loss Carryforwards 27.1M USD -0.75%
Preferred Stock, Shares Issued 250K shares 0%
Preferred Stock, Shares Authorized 2M shares 0%
Additional Paid in Capital 105M USD +13.9%
Preferred Stock, Shares Outstanding 250K shares 0%
Share-based Payment Arrangement, Expense 1.24M USD +36.4%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%